We evaluated the efficacy 131I-VCN in prolonging the progression-free survival of study animals in two distinct xenograft models of glioma that are devoid of O-6-methylguanine methyltransferase (MGMT) expression (i.e., U87 and U251) and therefore sensitive to TMZ. Here, MGMT is linked to glioma.